This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Phil Gunby

JAMA. 1980;243(1):11.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Experimental use of the oral agent isotretinoin (13-cis-retinoic acid) has produced extensive remissions of cystic and conglobate acne so far in two series, totaling 47 patients. Less clear are the drug's effects on various keratinizing dermatoses and basal cell carcinomas.

The retinoids, a family of compounds that includes both synthetic and natural forms of vitamin A, appear to have effects on cell maturation and differentiation. Because of this, isotretinoin is being used also in a clinical chemoprevention trial with volunteers who are at high risk for bladder cancer (JAMA [MEDICAL NEWS] 240:609-610, 614-615, 1978).

During the American Academy of Dermatology's annual meeting in Chicago, some results to date in the cutaneous trials were discussed by Gary L. Peck, MD, senior investigator, Dermatology Branch, National Cancer Institute (NCI), Bethesda, Md, and Dorothy B. Windhorst, MD, director of clinical research for dermatology, Hoffmann-La Roche Inc, Nutley, NJ.

Peck said that the antibiotic-resistant . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?